English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Results Study Population  1433 adults from 21 countries were randomized and treated in GEMINI-1 and -2 Introduction  Two-drug regimens (2DRs) are being evaluated against standard 3-drug regimens for their potential to reduce cumulative drug exposure and drug–drug interactions during lifelong antiretroviral therapy (ART) in people living with HIV  We evaluated the 2DR of DTG + 3TC in 2 identical global, double-blind, multicenter, phase III studies GEMINI-1 and -2 (ClinicalTrials.gov: NCT02831673/NCT02831764)  Primary endpoint results were previously presented: DTG + 3TC was non-inferior to DTG + TDF/FTC at Week 48. No participants who met protocol-defined virologic withdrawal criteria had treatment-emergent INSTI or NRTI resistance mutations1

journal of infection and public health

Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies